Literature DB >> 21808159

Pain in critically ill patients with substance use disorder or long-term opioid use for chronic pain.

Debra J Drew1, Barbara J St Marie.   

Abstract

Opioid tolerance resulting from long-term opioid consumption for chronic pain or from substance use disorder adds a layer of complexity to managing pain in the critical care setting. This article discusses similarities and differences of these 2 conditions. The phenomenon of tolerance and opioid-induced hyperalgesia are presented. Prevention of opioid withdrawal, when patients are on methadone or buprenorphine, is described. An overview of the neurophysiology of pain and substance use disorder is presented. Practical clinical suggestions are given to assist the critical care nurse in caring for these complex patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21808159     DOI: 10.1097/NCI.0b013e318220c504

Source DB:  PubMed          Journal:  AACN Adv Crit Care        ISSN: 1559-7768


  4 in total

Review 1.  [Pain therapy in intensive care patients].

Authors:  Katharina Rose; Winfried Meißner
Journal:  Anaesthesist       Date:  2018-06       Impact factor: 1.041

2.  American Society for Pain Management nursing position statement: pain management in patients with substance use disorders.

Authors:  June Oliver; Candace Coggins; Peggy Compton; Susan Hagan; Deborah Matteliano; Marsha Stanton; Barbara St Marie; Stephen Strobbe; Helen N Turner
Journal:  J Addict Nurs       Date:  2012-10       Impact factor: 1.476

Review 3.  Managing Pain in the Setting of Opioid Use Disorder.

Authors:  Barbara St Marie; Kathleen Broglio
Journal:  Pain Manag Nurs       Date:  2019-10-21       Impact factor: 1.929

4.  American Society for Pain Management nursing position statement: pain management in patients with substance use disorders.

Authors:  June Oliver; Candace Coggins; Peggy Compton; Susan Hagan; Deborah Matteliano; Marsha Stanton; Barbara St Marie; Stephen Strobbe; Helen N Turner
Journal:  Pain Manag Nurs       Date:  2012-09       Impact factor: 1.929

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.